PALATINE, IL--(Marketwire - Jul 25, 2012) - Acura Pharmaceuticals, Inc. (
To participate in the live conference call, please dial 800-967-7140 (U.S. and Canada) or 719-457-2632 (international) five to ten minutes prior to the start of the call. The participant passcode is 8419237. A live audio webcast will also be available through the "Investors" section of the company's website, http://www.acurapharm.com.
A replay of the call will be available beginning August 8, 2012 at 11:30 a.m. ET and ending on August 22, 2012 on the company's website, and by dialing 888-203-1112 (U.S. and Canada) or 719-457-0820 (international). The replay participant code is 8419237.
About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE™ technologies. In June 2011, the U.S. Food and Drug Administration, or FDA, approved OXECTA® which incorporates the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products including other opioids and it's IMPEDE technology for pseudoephedrine hydrochloride products.
Contact Information:
Contact:
David Carey for Acura Investor Relations
investors@acurapharm.com
212-867-1762
Chris Seger for Acura Media Relations
pr@acurapharm.com
212-867-1762